September 2024 – Page 34

Autoimmune Hepatitis Treatment Market Size is expected to increase by 2034, estimates DelveInsight

Autoimmune Hepatitis Treatment Market is projected to witness substantial growth over the next few years, driven by advancements in treatment modalities and increasing awareness of the condition. The pipeline for Autoimmune Hepatitis Therapeutics includes promising candidates that aim to not only treat acute attacks but also prevent recurrence.

DelveInsight’s “Autoimmune Hepatitis Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the Autoimmune Hepatitis, historical and forecasted epidemiology as well as the Autoimmune Hepatitis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Unlock detailed insights into the Autoimmune Hepatitis Market by downloading the comprehensive report from DelveInsight @ Autoimmune Hepatitis Therapeutics Market

Key Takeaways from the Autoimmune Hepatitis Market Report

In August 2024:- Novartis Pharmaceuticals- Patients will be randomly assigned to different doses of VAY736 or placebo. The primary analysis is planned at 24 weeks. A subsequent study part will then test the efficacy and safety of VAY736 in a parallel group design. For this part of the trial a new group of autoimmune hepatitis patients will be enrolled.
In August 2024:- Kezar Life Sciences, Inc.- This is a Phase 2a, multi-center, placebo-controlled study in which patients with autoimmune hepatitis will receive zetomipzomib or placebo in addition to standard-of-care for 24 weeks; an optional open-label extension period allows patients to receive zetomipzomib (KZR-616) for an additional 24 weeks of treatment.
According to the American Liver Foundation, Autoimmune Hepatitis (AIH) is a disease in which the body’s immune system attacks the liver and causes it to become inflamed. The disease is chronic, meaning it lasts many years. If untreated, it can lead to cirrhosis and liver failure.
It was found that the prevalence of AIH in the US is approximately 31.2 per 100,000 individuals.
The leading Autoimmune Hepatitis Companies such as Abbott Laboratories, AbbVie, Inc., Arihantanam Life Care Pvt Ltd., AstraZeneca PLC, Bayer AG, Biocon, Ltd., Bio-Rad Laboratories, Inc., Bristol-Myers Squibb Co., Cipla, Ltd., GlaxoSmithKline PLC, Gilead Life sciences, Inc., Johnson & Johnson Services, Inc., Inova Diagnostics, Inc., Merck & Co., Inc., Novartis International AG, Organovo Holdings, Inc., Pfizer, Inc., Upcyte Technologies GmbH, and others.
Promising Autoimmune Hepatitis Therapies such as VAY736, HR19042 Capsules, zetomipzomib, and others.

Gain a competitive edge in the Autoimmune Hepatitis Market by exploring our in-depth analysis. Visit our website to access the full report and make informed strategic decisions @ Autoimmune Hepatitis Treatment Drugs

Autoimmune Hepatitis Epidemiology Segmentation in the 7MM

Total Autoimmune Hepatitis Prevalent Cases
Autoimmune Hepatitis Gender-specific Diagnosed Prevalent Cases
Autoimmune Hepatitis Type-specific Diagnosed Prevalent Cases
Total Autoimmune Hepatitis Diagnosed Prevalent Cases
Autoimmune Hepatitis Age-specific Diagnosed Prevalent Cases
Autoimmune Hepatitis Treated Cases

Autoimmune Hepatitis Market Insights

The goal of treatment of AIH is to stop the body’s attack on itself by suppressing the immune system. The basic treatment is the administration of immunosuppressive drugs, the first of which is the oral drug corticosteroid. Medications help to regulate an overactive immune system. Both type 1 and type 2 autoimmune hepatitis are commonly treated with daily doses of the steroid prednisone. Initially, a high dose may be prescribed, which will be gradually reduced as the disease is controlled. The aim is to determine the lowest effective dose that manages the condition.

Discover key developments and opportunities in the Autoimmune Hepatitis Market. Click here to learn more from DelveInsight’s latest report @ Autoimmune Hepatitis Market Size

Autoimmune Hepatitis Treatment Market Landscape

The Autoimmune Hepatitis treatment market is shifting towards personalized and precision medicine. Efforts are focused on understanding the underlying disease mechanisms to tailor therapies more effectively to individual patients. This includes exploring genetic and molecular profiles to guide treatment decisions and improve outcomes. The emphasis is increasingly on integrating innovative research findings to address the limitations of current treatments and enhance patient care.

Autoimmune Hepatitis Emerging Drugs Profile

Zetomipzomib (KZR-616): Kezar Life Sciences
Ianalumab (VAY736): Novartis/MorphoSys

Download DelveInsight’s Autoimmune Hepatitis Market report today and stay ahead in this rapidly evolving field. @ Autoimmune Hepatitis Clinical Trials

Scope of the Autoimmune Hepatitis Market Report

Coverage- 7MM
Autoimmune Hepatitis Companies- Abbott Laboratories, AbbVie, Inc., Arihantanam Life Care Pvt Ltd., AstraZeneca PLC, Bayer AG, Biocon, Ltd., Bio-Rad Laboratories, Inc., Bristol-Myers Squibb Co., Cipla, Ltd., GlaxoSmithKline PLC, Gilead Life sciences, Inc., Johnson & Johnson Services, Inc., Inova Diagnostics, Inc., Merck & Co., Inc., Novartis International AG, Organovo Holdings, Inc., Pfizer, Inc., Upcyte Technologies GmbH, and others.
Autoimmune Hepatitis Therapies- VAY736, HR19042 Capsules, zetomipzomib, and others.
Autoimmune Hepatitis Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
Autoimmune Hepatitis Unmet Needs, KOL’s views, Analyst’s views, Autoimmune Hepatitis Market Access and Reimbursement

Download the report to understand which factors are driving Autoimmune Hepatitis Market Trends @ Autoimmune Hepatitis Market Trends

Table of Content

1. Key Insights

2. Executive Summary of Autoimmune Hepatitis

3. Competitive Intelligence Analysis for Autoimmune Hepatitis

4. Autoimmune Hepatitis: Market Overview at a Glance

5. Autoimmune Hepatitis: Disease Background and Overview

6. Patient Journey

7. Autoimmune Hepatitis Epidemiology and Patient Population

8. Treatment Algorithm, Current Treatment, and Medical Practices

9. Autoimmune Hepatitis Unmet Needs

10. Key Endpoints of Autoimmune Hepatitis Treatment

11. Autoimmune Hepatitis Marketed Products

12. Autoimmune Hepatitis Emerging Therapies

13. Autoimmune Hepatitis: Seven Major Market Analysis

14. Attribute analysis

15. 7MM: Market Outlook

16. Access and Reimbursement Overview of Autoimmune Hepatitis

17. KOL Views

18. Market Drivers

19. Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

23. About DelveInsight

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Autoimmune Hepatitis Treatment Market Size is expected to increase by 2034, estimates DelveInsight

Needle Holder Market: USD 367.3M in 2024 to USD 530.3M by 2029, CAGR 7.6%

“Major players in Needle holder market include B. Braun Melsungen Ag (Germany), Olympus Corporation (Japan), Karl Storz (Germany), Teleflex Incorporated (US), Integra LifeSciences Holdings Corporation (US), and Stille AB (Sweden).”

Browse 280 market data Tables and 40 Figures spread through 250 Pages and in-depth TOC on “Needle Holder Market by Type (Mayo-Hegar, Olsen-Hegar, Crilewood, Derf, Castroviejo), Application (Surgery, Microsurgery, Dental), Material (Stainless Steel, Tungsten Carbide), Usage Type (Reusable, Single Use), End User, Region – Global Forecast to 2029

The global needle holder market is forecasted to grow from USD 367.3 million in 2024 to USD 530.3 million by 2029, reflecting a CAGR of 7.6%. This growth is driven by increased investments in healthcare, a rise in surgeries including microsurgeries and cosmetic procedures, and the expansion of outpatient surgeries. Key players in this market include B. Braun Melsungen AG, Olympus Corporation, Karl Storz, Teleflex Incorporated, Integra LifeSciences Holdings Corporation, and Stille AB. Major trends include the dominance of reusable needle holders, with a particular growth in the Mayo-Hegar segment and a shift towards microsurgeries. Challenges such as the high cost of surgeries and the rise of non-surgical techniques like robotic-assisted surgeries could impact market expansion. North America is expected to lead the market due to its advanced healthcare infrastructure and high surgery volumes.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=260494054

Market Segmentation by Type

The needle holder market is categorized into several types: Castroviejo, Olsen-Hegar, Mayo-Hegar, Derf, Crile-Wood, and others. As of 2023, the Mayo-Hegar Needle Holder holds the largest market share due to its widespread use in various surgeries such as general, cardiovascular, and orthopedic. The Castroviejo Needle Holder is experiencing the highest growth rate due to the increasing demand for microsurgeries.

Market Segmentation by Application

The needle holder market is segmented by application into surgery, microsurgery, and dental procedures. The surgery segment held the largest market share in 2023, driven by the rising number of chronic disease patients and surgeries, particularly among individuals over 60 years old. Microsurgery is also growing as there is a shift towards more advanced surgical techniques.

Market Segmentation by End User

The needle holder market is divided into hospitals & ambulatory surgery centers (ASCs) and other end users. In 2023, hospitals & ASCs held the largest market share. This is attributed to the high volume of outpatient surgeries performed in ASCs, which offer convenience, quicker recovery, and lower costs for patients. The growth of hospitals and ASCs is expected to further drive market demand for needle holders.

Regional Market Analysis

Regionally, the needle holder market is segmented into North America, Europe, Asia Pacific, Latin America, the Middle East & Africa, and GCC. North America dominated the market in 2023 due to significant government investments in healthcare, new hospital construction, and favorable healthcare reforms. The Asia Pacific region is projected to experience the highest CAGR, driven by a large patient population over 60 years old, who are more susceptible to chronic diseases.

Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=260494054

Market Dynamics and Key Players

The needle holder market is concentrated, with a few major players dominating the space. Key companies include B. Braun Melsungen AG (Germany), Olympus Corporation (Japan), Karl Storz (Germany), Teleflex Incorporated (US), Integra LifeSciences Holdings Corporation (US), and Stille AB (Sweden).

B. Braun Melsungen AG

In 2023, B. Braun Melsungen AG led the needle holder market. The company maintains its top position through extensive distribution networks across North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. B. Braun is a major manufacturer of surgical and microsurgical instruments, including needle holders used in a variety of surgeries such as cardiac, plastic, and orthopedic, contributing to its significant market share.

Olympus Corporation

Olympus Corporation held the second position in the needle holder market in 2023. Known for its trusted brand in the medical device industry, Olympus continues to invest heavily in research and development (R&D), increasing its R&D spending to USD 447 million in 2023 from USD 442 million in 2022. This investment supports Olympus in maintaining its competitive edge and enhancing its product offerings.

Teleflex Incorporated

Teleflex Incorporated ranked third in the needle holder market in 2023. The company offers a range of needle holders used in various surgical procedures and focuses on expanding its global reach. Operating in over 150 countries, Teleflex’s strategic expansion efforts help reduce its reliance on any single market, broadening its market presence and strengthening its product portfolio.

For more information, Inquire Now!

Media Contact
Company Name: MarketsandMarkets™ Research Private Ltd.
Contact Person: Mr. Aashish Mehra
Email: Send Email
Phone: 18886006441
Address:630 Dundee Road Suite 430
City: Northbrook
State: IL 60062
Country: United States
Website: https://www.prnewswire.com/news-releases/needle-holder-market-usd-367-3m-in-2024-to-usd-530-3m-by-2029–cagr-7-6–marketsandmarkets-302247478.html

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Needle Holder Market: USD 367.3M in 2024 to USD 530.3M by 2029, CAGR 7.6%

Asthma Treatment Market Size in the 7MM was ~USD 19,000 million in 2023, estimated DelveInsight

Asthma Treatment Market is projected to witness substantial growth over the next few years, driven by advancements in treatment modalities and increasing awareness of the condition. The pipeline for Asthma Therapeutics includes promising candidates that aim to not only treat acute attacks but also prevent recurrence.

DelveInsight’s “Asthma Market Insights, Epidemiology and Market Forecast – 2034” report delivers an in-depth understanding of the Asthma, historical and forecasted epidemiology as well as the Asthma market trends in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.

Unlock detailed insights into the Asthma Market by downloading the comprehensive report from DelveInsight @ Asthma Market

Key Takeaways from the Asthma Market Report

In September 2024:- AstraZeneca- A Randomised, Double-blind, Parallel Group, Placebo Controlled, 4-Week, Phase II Study to Evaluate the Effect of AZD4604 on Airway Inflammation and Biomarkers in Adults With Asthma. The purpose of this study is to investigate the effect on airway inflammation and JAK1-associated signalling pathways of AZD4604 compared with placebo in participants with moderate-to-severe asthma.
In September 2024:- Chiesi Farmaceutici S.p.A.- The purpose of this study is to evaluate the efficacy and safety of CHF6001 (Tanimilast) as add-on to maintenance of inhaled corticosteroids in combination with Long-acting ß2-agonists in the target patient population. (TANGO)
As per DelveInsight analysis, there were approximately 55 million diagnosed prevalent cases of asthma, in the 7MM, in 2023. These cases are projected to increase during the forecast period (2024-2034).
Among the 7MM, the US accounted for the highest, approximately 47% of the total diagnosed prevalent cases in 2023, while Spain accounted for the least with nearly 5% of the total.
According to DelveInsight analysis, there were around 4.8 million pediatrics and 21.2 million adults cases of asthma in the US in 2023, with numbers expected to rise by 2034.
The leading Asthma Companies such as Cipla Ltd, Hamad Medical Corporation, Areteia Therapeutics, AstraZeneca, Amgen, GSK, Sanofi, TEVA Pharmaceutical, Regeneron Pharmaceuticals, Shanghai Hengrui Pharmaceutical Co., Ltd., Novartis Pharmaceuticals, and others.
Promising Asthma Therapies such as Dexpramipexole Dihydrochloride, Benralizumab, Dupilumab, Rocatinlimab, Mepolizumab, Tezepelumab, GSK3511294 (Depemokimab), and others.

Gain a competitive edge in the Asthma Market by exploring our in-depth analysis. Visit our website to access the full report and make informed strategic decisions @ Asthma Treatment Drugs

Asthma Epidemiology Segmentation in the 7MM

Total Diagnosed Prevalent Cases
Age-specific Cases
Gender-specific Cases
Severity-specific Cases
Type-specific Severity Cases

Asthma Treatment Market

The mainstay treatment for persistent asthma consists of inhaled corticosteroids. Quick-relief (reliever) or rescue medicines quickly ease symptoms that arise acutely. Short-acting beta-agonists (SABAs) rapidly reduce airway bronchoconstriction and are recommended rescue medication for rapid symptom relief. Additional long-term controller medicines, such as long-acting beta 2 agonists (LABA), montelukast, or theophylline, are added if asthma is still uncontrolled.

Discover key developments and opportunities in the Asthma Market. Click here to learn more from DelveInsight’s latest report @ Asthma Market Size

Asthma Marketed Drugs

TEZSPIRE (tezepelumab-ekko): Amgen/AstraZeneca

TEZSPIRE (tezepelumab) was developed by AstraZeneca in collaboration with Amgen as a first-in-class human monoclonal antibody that inhibits the action of TSLP, a key epithelial cytokine that sits at the top of multiple inflammatory cascades and is critical in the initiation and persistence of allergic, eosinophilic and other types of airway inflammation associated with severe Asthma, including airway hyperresponsivenes. It is approved in the US, EU, Japan, and other countries for treating severe Asthma.

CINQAIR (reslizumab): Teva Pharmaceutical

Reslizumab injection is a humanized interleukin-5 antagonist monoclonal antibody for add-on maintenance treatment of adult patients with severe Asthma and an eosinophilic phenotype developed by Teva Pharmaceuticals. CINQAIR is indicated for the add-on maintenance treatment of patients with severe Asthma aged 18 and older with an eosinophilic phenotype. It is approved in the US, EU, but not in Japan.

FASENRA (benralizumab): AstraZeneca

FASENRA (benralizumab) is a monoclonal antibody that binds directly to the IL-5 receptor alpha on eosinophils and attracts natural killer cells to induce rapid and near-complete depletion of eosinophils via apoptosis (programmed cell death). FASENRA is AstraZeneca’s first respiratory biologic, approved as an add-on maintenance treatment in severe eosinophilic Asthma in the US, EU, Japan, and other countries, with further regulatory reviews ongoing.

Asthma Emerging Drugs

GSK3511294 (Depemokimab): GlaxoSmithKline

GSK is developing GSK3511294 (depemokimab), a humanized anti-interleukin (IL)-5 monoclonal antibody, to treat severe eosinophilic Asthma. As a new biological entity, it is engineered to ensure high affinity and long-acting suppression of IL-5 functions. IL-5 is cytokines responsible for the proliferation, activation, and survival of eosinophils, thus making them a proven treatment target for severe Asthma patients with higher levels of eosinophils. Depemokimab, with an extended half-life and improved IL-5 affinity compared to other approved therapies, is the first biologic to be administered subcutaneously once every 26 weeks.

PT010: AstraZeneca

PT010, being developed by AstraZeneca, is a fixed-dose combination of micronized budesonide, an inhaled corticosteroid (ICS), micronized glycopyrrolate (an anticholinergic), and micronized formoterol fumarate, a LABA, for oral inhalation administered via a pressurized metered-dose inhaler (pMDI) using Aerosphere delivery technology. AstraZeneca is conducting multiple Phase III trials to assess the safety and efficacy of PT010 in adults and adolescents with severe Asthma inadequately controlled with the standard of care.

Asthma Market Outlook

The goal of treatment is to minimize symptom burden (i.e., maintain normal activity levels while maintaining good symptom control) and reduce the possibility of adverse events such as fixed airflow limitation, exacerbations, and therapeutic side effects. Guidelines-based Asthma management emphasizes the severity of the condition and selecting the best medical treatment to manage symptoms and lower the likelihood of exacerbations.

Download DelveInsight’s Asthma Market report today and stay ahead in this rapidly evolving field. @ Asthma Clinical Trials

Scope of the Asthma Market Report

Coverage- 7MM
Asthma Companies- Cipla Ltd, Hamad Medical Corporation, Areteia Therapeutics, AstraZeneca, Amgen, GSK, Sanofi, TEVA Pharmaceutical, Regeneron Pharmaceuticals, Shanghai Hengrui Pharmaceutical Co., Ltd., Novartis Pharmaceuticals, and others.
Asthma Therapies- Dexpramipexole Dihydrochloride, Benralizumab, Dupilumab, Rocatinlimab, Mepolizumab, Tezepelumab, GSK3511294 (Depemokimab), and others.
Asthma Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
Asthma Unmet Needs, KOL’s views, Analyst’s views, Asthma Market Access and Reimbursement

Download the report to understand which factors are driving Asthma Market Trends @ Asthma Market Trends

Table of Content

1 Key Insights

2 Report Introduction

3 Asthma Market Overview at a Glance

4 Methodology of Asthma Epidemiology and Market

5 Executive Summary of Asthma

6 Key Events

7 Disease Background and Overview

8 Epidemiology and Patient Population

9 Patient Journey

10 Marketed Therapies

11 Emerging Therapies

12 Asthma: Market Analysis

13 KOL Views

14 SWOT Analysis

15 Unmet needs

16 Market Access and Reimbursement

17 Appendix

18 DelveInsight Capabilities

19 Disclaimer

About Us

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Asthma Treatment Market Size in the 7MM was ~USD 19,000 million in 2023, estimated DelveInsight

Cardiac Tissue Engineering Market to Reach USD 1,333.6 M by 2029, Driven by Stem Cell Research and Support

“Prominent players in the Cardiac Tissue Engineering market include, Terumo corporation (Japan), Artivion, Inc. (US), Baxter international, Inc. (US), Teijin Limited (Japan), Medtronic Plc. (Ireland), Boston Scientific Corporation (US), Abbott Laboratories (US), Merck KGaA (Germany), Elutia. (US), W. L. Gore & Associates, Inc. (US), Meril Lifesciences Pvt.Ltd (India)”

Browse 426 market data Tables and 54 Figures spread through 336 Pages and in-depth TOC on “Cardiac Tissue Engineering Market by Material (Scaffold, Stem cells), Product (Heart Valve, Vascular Grafts), Applications (MI,Congenital Heart Disease), End-User (Hospitals & Clinics, Academics & Research Institutes) – Global Forecast to 2029

The cardiac tissue engineering market is expected to grow from USD 621.2 million in 2024 to USD 1,333.6 million by 2029, reflecting a compound annual growth rate (CAGR) of 16.5%. This growth is driven by increased demand for regenerative medicine, advancements in 3D bioprinting, and rising cardiovascular disease prevalence. Key market drivers include substantial support from government and major market players, exemplified by a CAD 23.6 million fundraising campaign in Canada. However, high treatment costs pose a significant restraint, limiting access to affluent patients and well-funded healthcare systems. Opportunities for growth are bolstered by the rising demand for stem cell research, while challenges include limited awareness about cardiac tissue engineering. Major companies in the field include Terumo Corporation, Artivion, Baxter International, and Medtronic, with North America leading the market due to high healthcare spending and advanced medical infrastructure.

Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=264276500

Material Segmentation

The market is divided into stem cells and scaffolds, with scaffolds further categorized into biological and synthetic types. In 2023, biological scaffolds held a significant market share due to their superior biological activity, which enhances cell adhesion and growth, and their ability to seamlessly integrate with the host’s extracellular matrix. This integration minimizes adverse immune reactions and supports natural tissue regeneration. In contrast, synthetic scaffolds, including polystyrene and poly-l-lactic acid (PLLA), face challenges such as reduced bioactivity and complications with degradation processes, making biological scaffolds a preferred option for cardiac tissue engineering.

Product Segmentation

The cardiac tissue engineering market includes vascular grafts, cardiac patches, and heart valves. In 2023, cardiac patches represented a significant portion of the market due to their multifunctional therapeutic capabilities. These patches, which may be composed of scaffolds or contain therapeutic agents, provide crucial mechanical support to weakened myocardial tissue and enhance heart function by promoting synchronized electrical conduction. Their ability to deliver targeted therapies directly to the infarct zone while minimizing systemic side effects makes them a vital component in cardiac repair and regeneration, contributing to their substantial market presence.

Application Segmentation

The market is categorized into myocardial infarction, heart valve repair/replacement, congenital heart disease treatment, and other applications. In 2023, the myocardial infarction segment held the largest share due to its high global prevalence and significant mortality rate. As myocardial infarction remains a leading cause of death worldwide, there is a pressing need for advanced therapeutic solutions. Cardiac tissue engineering offers innovative methods to repair and regenerate damaged heart tissue, addressing critical clinical challenges and driving substantial investment and research in this area.

Regional Growth

The cardiac tissue engineering market is divided into five major regions: North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa. In 2023, Asia Pacific emerged as the fastest-growing region, driven by a rising prevalence of cardiovascular diseases, largely due to an aging population. According to the Economic and Social Commission for Asia and the Pacific (ESCAP), the region’s elderly population is expected to double by 2050, increasing the demand for advanced cardiac treatments. This demographic shift, coupled with a surge in cardiovascular conditions, is accelerating investments in research, healthcare infrastructure, and innovative therapies, solidifying Asia Pacific’s leading growth position in the market.

Request Sample Pages: https://www.marketsandmarkets.com/requestsampleNew.asp?id=264276500

Key Market Players

The cardiac tissue engineering market is dominated by several major players, including Terumo Corporation (Japan), Artivion, Inc. (US), Baxter International, Inc. (US), Teijin Limited (Japan), Medtronic Plc (Ireland), Boston Scientific Corporation (US), Abbott Laboratories (US), Merck KGaA (Germany), Elutia (US), W. L. Gore & Associates, Inc. (US), Meril Lifesciences Pvt. Ltd. (India), Fujifilm Holdings Corporation (Japan), Vascudyne, Inc. (US), BICO – THE BIO CONVERGENCE COMPANY (Sweden), ReproCELL, Inc. (US), PromoCell GmbH (Germany), Axol Bioscience Ltd. (UK), BPS Bioscience, Inc. (US), Cell Application, Inc. (US), and Viscofan DE GmbH (Germany).

Terumo Corporation (Japan)

Terumo Corporation is a leading player in the cardiac tissue engineering market, recognized for its HeartSheet product derived from autologous skeletal myoblast sheets. This product is designed to treat heart failure caused by chronic ischemic disease and has gained approval under Japan’s expedited regulatory framework for regenerative medicine. Terumo’s extensive global reach, spanning over 160 countries, and its comprehensive cardiovascular division enhance its position in the industry. The company’s focus on innovative product development and global distribution underlines its leadership and capability in addressing diverse cardiac care needs.

Artivion, Inc. (US)

Artivion, Inc., previously known as CryoLife Inc., is a notable player in the cardiac tissue engineering sector, particularly recognized for its SynerGraft product. This product helps to reduce immune rejection risk while supporting natural tissue regeneration. Artivion’s strategic presence across multiple regions, including North America, Europe, the Middle East, Africa, Asia Pacific, and Latin America, ensures broad accessibility to its advanced medical devices and implantable human tissues. This extensive reach supports global adoption and reinforces Artivion’s role in advancing cardiac care solutions.

Baxter International, Inc. (US)

Baxter International Inc. stands out in the cardiac tissue engineering market for its innovative contributions to medical technology and regenerative therapies. The company’s advanced surgery segment offers Peri-Guard and Supple Peri-Guard products for cardiothoracic surgery, made from bovine pericardium. These products are noted for their exceptionally low adverse event rate of less than 0.07%. Baxter’s extensive global network, including the US, Europe, the Middle East, Africa, Latin America, Asia, Canada, Japan, Australia, and New Zealand, ensures wide availability of its high-quality cardiac solutions, reinforcing its significant role in the market.

For more information, inquire now! Inquire Now

Media Contact
Company Name: MarketsandMarkets™ Research Private Ltd.
Contact Person: Mr. Aashish Mehra
Email: Send Email
Phone: 18886006441
Address:630 Dundee Road Suite 430
City: Northbrook
State: IL 60062
Country: United States
Website: https://www.prnewswire.com/news-releases/cardiac-tissue-engineering-market-to-reach-usd-1-333-6-m-by-2029–driven-by-stem-cell-research-and-support–marketsandmarkets-302241717.html

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Cardiac Tissue Engineering Market to Reach USD 1,333.6 M by 2029, Driven by Stem Cell Research and Support

Toll-Like Receptor 4 (TLR-4) Agonist Pipeline Insights, Treatment Drugs, Clinical Trials, and Companies 2024

DelveInsight’s, “Toll-Like Receptor 4 (TLR-4) Agonist Pipeline Insight, 2024,” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Toll-Like Receptor 4 (TLR-4) Agonist pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Discover the latest drugs and treatment options in the Toll-Like Receptor 4 (TLR-4) Agonist Pipeline. Dive into DelveInsight’s comprehensive report today! @ Toll-Like Receptor 4 (TLR-4) Agonist Pipeline Outlook

Key Takeaways from the Toll-Like Receptor 4 (TLR-4) Agonist Pipeline Report

In August 2024:- Jonsson Comprehensive Cancer Center- The main purpose of this study is to evaluate the most effective immunotherapy vaccine components in patients with malignant glioma. Teh investigators previous phase I study (IRB #03-04-053) already confirmed that this vaccine procedure is safe in patients with malignant brain tumors, and with an indication of extended survival in several patients.
In July 2024:- Baylor College of Medicine- This study evaluates the efficacy, safety and immunogenicity of different formulations of the Na-GST-1 hookworm vaccine using a controlled human hookworm infection model in healthy, hookworm-naive adults.
DelveInsight’s Toll-Like Receptor 4 (TLR-4) Agonist pipeline report depicts a robust space with 10+ active players working to develop 10+ pipeline therapies for Toll-Like Receptor 4 (TLR-4) Agonist treatment.
The leading Toll-Like Receptor 4 (TLR-4) Agonist Companies such as Eisai, Akaza Bioscience, OPNT-003, GeNeuro, MN-166 (ibudilast), Orexo, and others.
Promising Toll-Like Receptor 4 (TLR-4) Agonist Therapies such as P2PAR-100, SBT8230, RG 6115, TransCon TLR 7/8 agonist, NKTR-262, BNT411, BO112, PrEP-001, BDB001, Cobitolimod, Tilsotolimod, SD 101, Lefitolimod, Vesatolimod, Vidutolimod, Rintatolimod, DUET 01, NJB 834, INNA 051, Glycopyranosyl lipid adjuvant, G 100, TARA-002, RO 7020531, Resiquimod, BDC 1001, SHR 2150, LHC 165, PRX 034, ELI 002, IDX 9059, Entolimod, and others.

Stay ahead with the most recent pipeline outlook for Toll-Like Receptor 4 (TLR-4) Agonist. Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ Toll-Like Receptor 4 (TLR-4) Agonist Treatment Drugs

Toll-Like Receptor 4 (TLR-4) Agonist Emerging Drugs Profile

E-5564: Eisai

E-5564 (Eritoran) is a TLR (Toll-Like Receptor) 4 antagonist created with natural product organic synthesis technology. It is a structural analogue of Lipid A which is an activator of endotoxins of bacteria. It is expected to suppress inflammation and increasing in severity caused by COVID-19 by inhibiting the activation of TLR4, which is found in the most upstream position of various cytokine gene expression signaling that causes the cytokine-storm. Development is in collaboration with GCAR (Global Coalition for Adaptive Research).

It is currently in Phase III stage of development and is being developed by Eisai.

TAK-242: Akaza Bioscience

TAK-242 acts as inhibitor of Toll-like receptor 4. Akaza Bioscience is preparing to run a Phase II study of TAK-242, a novel immunological therapy. This pan-European study aims to investigate the safety and efficacy of TAK-242, as measured by changes in key biomarkers and 28-day survival rates. The trial will be a randomised, double-blind, placebo-controlled study in patients with Grade 1 or 2 ACLF.

Explore groundbreaking therapies and clinical trials in the Toll-Like Receptor 4 (TLR-4) Agonist Pipeline. Access DelveInsight’s detailed report now! @ New Toll-Like Receptor 4 (TLR-4) Agonist Drugs

Toll-Like Receptor 4 (TLR-4) Agonist pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration.

Infusion
Intradermal
Intramuscular
Intranasal
Intravaginal
Oral
Parenteral
Subcutaneous
Topical
Molecule Type

Toll-Like Receptor 4 (TLR-4) Agonist Products have been categorized under various Molecule types such as

Vaccines
Monoclonal Antibody
Peptides
Polymer
Small molecule
Product Type

Unveil the future of Toll-Like Receptor 4 (TLR-4) Agonist Treatment. Learn about new drugs, pipeline developments, and key companies with DelveInsight’s expert analysis @ Toll-Like Receptor 4 (TLR-4) Agonist Market Drivers and Barriers

Scope of the Toll-Like Receptor 4 (TLR-4) Agonist Pipeline Report

Coverage- Global
Toll-Like Receptor 4 (TLR-4) Agonist Companies- Eisai, Akaza Bioscience, OPNT-003, GeNeuro, MN-166 (ibudilast), Orexo, and others.
Toll-Like Receptor 4 (TLR-4) Agonist Therapies- P2PAR-100, SBT8230, RG 6115, TransCon TLR 7/8 agonist, NKTR-262, BNT411, BO112, PrEP-001, BDB001, Cobitolimod, Tilsotolimod, SD 101, Lefitolimod, Vesatolimod, Vidutolimod, Rintatolimod, DUET 01, NJB 834, INNA 051, Glycopyranosyl lipid adjuvant, G 100, TARA-002, RO 7020531, Resiquimod, BDC 1001, SHR 2150, LHC 165, PRX 034, ELI 002, IDX 9059, Entolimod, and others.
Toll-Like Receptor 4 (TLR-4) Agonist Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
Toll-Like Receptor 4 (TLR-4) Agonist Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Get the latest on Toll-Like Receptor 4 (TLR-4) Agonist Therapies and clinical trials. Download DelveInsight’s in-depth pipeline report today! @ Toll-Like Receptor 4 (TLR-4) Agonist Companies, Key Products and Unmet Needs

Table of Content

Introduction
Executive Summary
Toll-Like Receptor 4 (TLR-4) Agonist: Overview
Pipeline Therapeutics
Therapeutic Assessment
Toll-Like Receptor 4 (TLR-4) Agonist– DelveInsight’s Analytical Perspective
In-depth Commercial Assessment
Toll-Like Receptor 4 (TLR-4) Agonist Collaboration Deals
Late Stage Products (Phase III)
E5564: Eisai
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
TAK-242: Akaza Bioscience
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
OX125: Orexo
Drug profiles in the detailed report…..
Preclinical and Discovery Stage Products
Drug Name: Company Name
Drug profiles in the detailed report…..
Inactive Products
Toll-Like Receptor 4 (TLR-4) Agonist Key Companies
Toll-Like Receptor 4 (TLR-4) Agonist Key Products
Toll-Like Receptor 4 (TLR-4) Agonist- Unmet Needs
Toll-Like Receptor 4 (TLR-4) Agonist- Market Drivers and Barriers
Toll-Like Receptor 4 (TLR-4) Agonist- Future Perspectives and Conclusion
Toll-Like Receptor 4 (TLR-4) Agonist Analyst Views
Toll-Like Receptor 4 (TLR-4) Agonist Key Companies
Appendix

About Us

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Toll-Like Receptor 4 (TLR-4) Agonist Pipeline Insights, Treatment Drugs, Clinical Trials, and Companies 2024

The Global Synthetic Biology Market to Hit $59.91 Billion by 2029, More than $44 Billion Opportunities in the Next 6 Years – Arizton

“Synthetic Biology Market Research Report by Arizton”

Industry Analysis Report, Regional Outlook, Growth Potential, Price Trends, Competitive Market Share & Forecast 2024–2029.

According to Arizton’s latest research report, the global synthetic biology market is growing at a CAGR of 25.68% during 2023-2029.

Looking for More Information? Click: https://www.arizton.com/market-reports/synthetic-biology-market

Report Scope:    

Market Size (2029): $59.91 Billion        

Market Size (2023): $15.20 Billion        

CAGR (2023-2029): 25.68%         

Historic Year:  2020-2022            

Base Year: 2023            

Forecast Year: 2024-2029            

Market Segmentation: Tool, Technology, Application, End-User, and Geography

Geographical Analysis: North America, Europe, APAC, Latin America, and Middle East & Africa    

Book the Free Sample Now: https://www.arizton.com/market-reports/synthetic-biology-market

The global synthetic biology market is highly competitive, with major players like Agilent Technologies, Codexis, Eurofins Scientific, Illumina, Novozymes, and Thermo Fisher Scientific commanding significant market shares. These leading companies face intense competition from both emerging and established players, driving ongoing technological innovation and product development across sectors such as healthcare, industrial applications, food and beverages, agriculture, and environmental solutions.

To sustain their market position and expand their reach, key players are focusing on organic growth strategies. This includes launching new products, enhancing existing ones, and securing patents for innovative technologies. These strategies are bolstered by substantial investments in research and development (R&D), which lead to valuable collaborations and acquisitions that enhance their product offerings and market expertise.

Despite the strong presence of major companies, the synthetic biology market presents substantial growth opportunities for smaller and emerging players. These companies are actively developing advanced synthetic biology tools and technologies, contributing to the market’s dynamic nature and fostering new opportunities for innovation and market entry. The increasing global demand for advanced healthcare solutions and other applications particularly drives this growth.

Strategic Initiatives and New Collaborations in the Synthetic Biology Market

Novozymes and Codexis are actively pursuing strategic initiatives to bolster their market presence, including the launch of new products and fostering collaborative efforts. Similarly, Agilent Technologies and Eurofins Scientific are key players focusing on introducing new products in targeted regions to increase their global market share.

In 2023, Sumitomo Chemical and Ginkgo Bioworks launched a new initiative to utilize synthetic biology to produce functional chemicals, marking their third collaborative project. Since 2021, the two companies have worked together on biomanufacturing solutions for personal care, cosmetics, agriculture, and pharmaceuticals. Their latest project is aimed at enabling large-scale production of functional chemicals through fermentation.

Key Vendors

Agilent Technologies
Codexis
Eurofins Scientific
Illumina
Novozymes
Thermo Fisher Scientific
Amyris
ATUM
Bio-Rad Laboratories
Creative Biogene
Creative Enzymes
Cyrus Biotechnology
Editas Medicine
Genomatica
Genscript
Ginkgo Bioworks
Integrated DNA Technologies
LGC Biosearch Technologies
New England Biolabs
OriGene Technologies
Precigen
Sentebiolab
SynbiCITE
Synthego
Tessera Therapeutics
Viridos
Asimov
Twist Bioscience
Mammoth Biosciences
ElevateBio
Dupont
DSM
Bota Biosciences
Kiverdi
Merck KGaA
Synlogic
Huee
Upside Foods

Pharma and Biotech Companies Lead Growth in Global Synthetic Biology Market

Pharma and biotech companies are experiencing the highest growth in the global synthetic biology market. These industries have been instrumental in the early achievements of synthetic biology, primarily due to its close relationship with small-molecule drug production. Many of these drugs are derived from natural sources, making it relatively easy to adapt microbial production systems. Additionally, the modular nature of many biosynthetic pathways, especially those used in producing bioactive natural products like antibiotics, aligns well with synthetic biology’s engineering techniques. These pathways evolved for rapid diversification and cross-species compatibility and often feature large modular assembly lines, providing ideal opportunities for applying synthetic biology approaches.

Segmentation & Forecast

Tool

Oligonucleotides and Synthetic DNA
Enzymes
Cloning Technology Kits
Xeno-Nucleic Acids
Chassis Organisms

Technology

Enabling Technology
Enabled Technology

Application

Healthcare Application
Industrial Application
Food & Agriculture Application
Environmental Application

End-User

Academic/Research Institutes & Laboratories
Pharma & Biotech Companies
Others

North America Leads the Global Synthetic Biology Market with Strong R&D and Regulatory Support

North America dominates the global synthetic biology market, holding the largest share. The region features a vibrant synthetic biology sector, with over 530 regenerative medicine companies specializing in cell and gene therapy and stem cell-based treatments. These companies are at the forefront of research and development, leveraging synthetic biology to advance medical treatments. The US excels in conducting clinical trials of cell and gene therapy, with a rising number of patients opting for these innovative therapies. Frequent regulatory approvals in North America further bolster the region’s leadership in synthetic biology.

Geography

North America

The U.S.
Canada

Europe

Germany
The U.K.
France
Italy
Spain

APAC

Japan
China
India
Australia
South Korea

Latin America

Brazil
Mexico
Argentina

Middle East & Africa

Turkey
South Africa
Saudi Arabia

In a nutshell, the Arizton Advisory & Intelligence market research report provides valuable market insights for industry stakeholders, investors, researchers, consultants, and business strategists aiming to gain a thorough understanding of the synthetic biology market. Request for Free Sample to get a glance at the report now: https://www.arizton.com/market-reports/synthetic-biology-market

What Key Findings Will Our Research Analysis Reveal?  

What are the key drivers of the global synthetic biology market?

How big is the global synthetic biology market?

Which region dominates the global synthetic biology market?

What is the growth rate of the global synthetic biology market?

Who are the major players in the global synthetic biology market?

Looking for Customization According to Your Business Requirement? https://www.arizton.com/customize-report/4490

Other Related Reports that Might be of Your Business Requirement  

Europe Cell And Gene Therapy Market – Focused Insights 2024-2029

The Europe cell and gene therapy market was valued at USD 2.26 billion in 2023 and is expected to reach USD 14.45 billion by 2029. Explore! https://www.arizton.com/market-reports/europe-cell-gene-therapy-market-size-analysis

Cell Counting Devices Market – Global Outlook & Forecast 2024-2029

The global cell counting devices market was valued at USD 12.39 billion in 2023 and is expected to reach USD 18.64 billion by 2029. Learn more about the market now: https://www.arizton.com/market-reports/cell-counting-devices-market

Why Arizton?                                             

100% Customer Satisfaction                                             

24×7 availability – we are always there when you need us                                             

200+ Fortune 500 Companies trust Arizton’s report                                             

80% of our reports are exclusive and first in the industry                                             

100% more data and analysis                                             

1500+ reports published till date                           

Post-Purchase Benefit                                         

1hr of free analyst discussion                                         
10% off on customization

About Us:                                                                                  

Arizton Advisory and Intelligence is an innovative and quality-driven firm that offers cutting-edge research solutions to clients worldwide. We excel in providing comprehensive market intelligence reports and advisory and consulting services.                                                                                

We offer comprehensive market research reports on consumer goods & retail technology, automotive and mobility, smart tech, healthcare, life sciences, industrial machinery, chemicals, materials, I.T. and media, logistics, and packaging. These reports contain detailed industry analysis, market size, share, growth drivers, and trend forecasts.                                                                                 

Arizton comprises a team of exuberant and well-experienced analysts who have mastered generating incisive reports. Our specialist analysts possess exemplary skills in market research. We train our team in advanced research practices, techniques, and ethics to outperform in fabricating impregnable research reports.                                                                                       

Media Contact
Company Name: Arizton Advisory & Intelligence
Contact Person: Jessica
Email: Send Email
Phone: +1-312-235-2040/+1 302 469 0707                                      
Country: United States
Website: https://www.arizton.com/market-reports/synthetic-biology-market

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: The Global Synthetic Biology Market to Hit $59.91 Billion by 2029, More than $44 Billion Opportunities in the Next 6 Years – Arizton

Atopic Dermatitis Pipeline Insights, Treatment Drugs, Clinical Trials, and Companies 2024

DelveInsight’s, “Atopic Dermatitis Pipeline Insight 2024” report provides comprehensive insights about 100+ companies and 110+ pipeline drugs in Atopic Dermatitis pipeline landscape. It covers the pipeline drug profiles, including Atopic Dermatitis clinical trials and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Discover the latest drugs and treatment options in the Atopic Dermatitis Pipeline. Dive into DelveInsight’s comprehensive report today! @ Atopic Dermatitis Pipeline Outlook

Key Takeaways from the Atopic Dermatitis Pipeline Report

In September 2024:- Aclaris Therapeutics Inc.- A Phase 2a Open-label Study to Investigate the Safety, Tolerability, Pharmacokinetics, Efficacy, and Pharmacodynamics of ATI-2138 Administered Over 12 Weeks in Participants With Moderate to Severe Atopic Dermatitis.
In September 2024:- Incyte Corporation- This study is being conducted to establish the efficacy of ruxolitinib cream in participants with moderate AD who had an inadequate response to, or are intolerant to, or contraindicated to topical corticosteroid (TCS)s and topical calcineurin inhibitor (TCI)s.
DelveInsight’s Atopic Dermatitis pipeline report depicts a robust space with 100+ active players working to develop 110+ pipeline therapies for Atopic Dermatitis treatment.
The leading Atopic Dermatitis Companies such as Dermavant Sciences, Pfizer, AOBiome, Allakos Inc., E-nitiate Biopharmaceuticals (Hangzhou) Co., Ltd., Eli Lilly and Company, Vanda Pharmaceuticals, Suzhou Connect Biopharmaceuticals, Arcutis Biotherapeutics, Reistone Biopharma, Alphyn Biologics, Argenx, Shulov Innovate for Science, Teres Bio, Qurient Co, Sun Pharmaceutical, Merck Sharp & Dohme LLC, Hangzhou Yirui Pharmaceutical Technology Co., Ltd, GI Innovation, AnaptysBio, MC2 Therapeutics, Akaal Pharma, Kiniksa Pharmaceuticals, Selection, Intrinsic Medicine, Genome & Company, TWi Biotechnology, and others.
Promising Atopic Dermatitis Therapies such as Dupilumab, APG777, ATI-2138, GSK1070806, HY209GEL, ADX-914, Rocatinlimab, TAVO101, and others.

Stay ahead with the most recent pipeline outlook for Atopic Dermatitis. Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ Atopic Dermatitis Treatment Drugs

Atopic Dermatitis Emerging Drugs Profile

Tapinarof: Dermavant Sciences

Tapinarof is a therapeutic aryl hydrocarbon receptor modulating agent (TAMA) that binds and activates the aryl hydrocarbon receptor in multiple cell types, including cells of the target tissue-human skin. Tapinarof has also shown to moderate proinflammatory cytokine expression in stimulated peripheral blood CD4+ T cells and ex vivo human skin, and impact barrier gene expression in primary human keratinocytes. The drug is currently being evaluated in Phase III stage of development for the treatment of patients with Atopic dermatitis.

Etrasimod: Pfizer

Etrasimod is an oral, once daily, selective sphingosine-1-phosphate (S1P) receptor modulator designed for optimized pharmacology and engagement of S1P receptors 1, 4, and 5. In addition to UC, it is being investigated for a range of other immuno-inflammatory diseases and is in Phase II/III stage of development for the treatment of patients with Atopic dermatitis.

B244: AOBiome

AOBiome’s B244 is a patented, proprietary, topical formulation incorporating a single strain of beneficial ammonia-oxidizing bacteria (AOB), Nitrosomonas eutropha D23. B244 is designed to repopulate the skin microbiome with AOBs normally found on the body but frequently stripped away by most soaps. Once deployed on the skin, B244 converts ammonia to nitrite, known to have antibacterial properties, and to nitric oxide, a signaling molecule known to regulate inflammation and vasodilation. The drug is currently being evaluated in Phase II stage of development for the treatment of patients with Atopic dermatitis.

Lirentelimab: Allakos Inc.

Lirentelimab (AK002) is an afucosylated, humanized IgG1 monoclonal antibody which activates the inhibitory receptor Siglec-8. Additionally, Lirentelimab depletes eosinophils via antibody dependent cellular cytotoxicity (ADCC) in blood. Siglec-8 is a member of the family of cell surface receptors called Sialic acid-binding immunoglobulin-type lectins (Siglecs). Allakos initiated a Phase II trial evaluating subcutaneous Lirentelimab versus placebo in patients with atopic dermatitis. Results from this trial are expected in the second half of 2023.

QY201: E-nitiate Biopharmaceuticals (Hangzhou) Co., Ltd.

QY201 acts on Jak1/Tyk2 dual targets with higher activity and selectivity, which is significantly superior to the similar drugs. QY201 is an innovative drug for the treatment of atopic dermatitis. QY201 was independently developed by E-nitiate with global patents, is undergoing Phase I/II clinical trial for atopic dermatitis.

Explore groundbreaking therapies and clinical trials in the Atopic Dermatitis Pipeline. Access DelveInsight’s detailed report now! @ New Atopic Dermatitis Drugs

Atopic Dermatitis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration

Oral
Intravenous
Subcutaneous
Parenteral
Topical

Atopic Dermatitis Products have been categorized under various Molecule types such as

Recombinant fusion proteins
Small molecule
Monoclonal antibody
Peptide
Polymer
Gene therapy

Unveil the future of Atopic Dermatitis Treatment. Learn about new drugs, pipeline developments, and key companies with DelveInsight’s expert analysis @ Atopic Dermatitis Market Drivers and Barriers

Scope of the Atopic Dermatitis Pipeline Report

Coverage- Global
Atopic Dermatitis Companies- Dermavant Sciences, Pfizer, AOBiome, Allakos Inc., E-nitiate Biopharmaceuticals (Hangzhou) Co., Ltd., Eli Lilly and Company, Vanda Pharmaceuticals, Suzhou Connect Biopharmaceuticals, Arcutis Biotherapeutics, Reistone Biopharma, Alphyn Biologics, Argenx, Shulov Innovate for Science, Teres Bio, Qurient Co, Sun Pharmaceutical, Merck Sharp & Dohme LLC, Hangzhou Yirui Pharmaceutical Technology Co., Ltd, GI Innovation, AnaptysBio, MC2 Therapeutics, Akaal Pharma, Kiniksa Pharmaceuticals, Selection, Intrinsic Medicine, Genome & Company, TWi Biotechnology, and others.
Atopic Dermatitis Therapies- Dupilumab, APG777, ATI-2138, GSK1070806, HY209GEL, ADX-914, Rocatinlimab, TAVO101, and others.
Atopic Dermatitis Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
Atopic Dermatitis Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Get the latest on Atopic Dermatitis Therapies and clinical trials. Download DelveInsight’s in-depth pipeline report today! @ Atopic Dermatitis Companies, Key Products and Unmet Needs

Table of Content

Introduction
Executive Summary
Atopic Dermatitis: Overview
Pipeline Therapeutics
Therapeutic Assessment
Atopic Dermatitis– DelveInsight’s Analytical Perspective
Late Stage Products (Phase III)
Tapinarof: Dermavant Sciences
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
B244: AOBiome
Drug profiles in the detailed report…..
Early Stage Products (Phase I/II)
QY201: E-nitiate Biopharmaceuticals (Hangzhou) Co., Ltd
Drug profiles in the detailed report…..
Preclinical and Discovery Stage Products
EP262: Escient Pharmaceuticals
Drug profiles in the detailed report…..
Inactive Products
Atopic Dermatitis Key Companies
Atopic Dermatitis Key Products
Atopic Dermatitis- Unmet Needs
Atopic Dermatitis- Market Drivers and Barriers
Atopic Dermatitis- Future Perspectives and Conclusion
Atopic Dermatitis Analyst Views
Atopic Dermatitis Key Companies
Appendix

About Us

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Atopic Dermatitis Pipeline Insights, Treatment Drugs, Clinical Trials, and Companies 2024

Security Testing Market Growing Trends, Business Growth, Size, Future Scope, Segmentation, Dynamics and Forecast to 2029

“IBM (US), HCLTech (India), Synopsys (US), OpenText (UK), Cigniti (US), Qualitest (UK), Intertek (UK), DXC Technology (US), eInfochips (US), Checkmarx (US), HackerOne (US), Invicti (US), DataArt (US), Cobalt Labs (US), Trustwave (US), Contrast Security (US), Veracode (US), Qualys (US), OffSec (US).”

Security Testing Market by Type (Network, Application, Device, Social Engineering), Network Security Testing (Penetration Testing, Vulnerability Scanning, Firewall), Application Testing Tools (RASP, SAST, DAST, IAST) – Global Forecast to 2029.

The global security testing market size is projected to grow from USD 14.5 billion in 2024 to USD 43.9 billion by 2029 at a Compound Annual Growth Rate (CAGR) of 24.7% during the forecast period. The sophistication and frequency of cyberattacks are rising, forcing enterprises to proactively detect and address vulnerabilities, which is driving the expansion of security testing. In addition, frequent security testing must ensure compliance and protect sensitive data due to strict regulatory requirements such as GDPR, HIPAA, and PCI DSS further fuels the market growth.

Download PDF Brochure@ https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=150407261

Based on the application testing tools, SAST accounts for the highest market size during the forecast period.

The adoption of Static Application Security Testing (SAST) tools is increasing as organizations prioritize secure software development. SAST tools enable developers to identify and fix security vulnerabilities early in the coding process, reducing the risk of security flaws in production. This shift is driven by the growing emphasis on integrating security into the software development lifecycle (SDLC) and the need to comply with stringent security standards. As a result, more companies are adopting SAST tools to enhance code security, improve development efficiency, and ensure that applications are robust against cyber threats from the outset.

By Application security testing type, web application security testing accounts for the highest market size during the forecast period.

The adoption of web application security testing is growing as organizations increasingly rely on web-based platforms for business operations and customer interactions. With the rise in cyber threats targeting web applications, such as SQL injection and cross-site scripting (XSS), companies are prioritizing security testing to identify and mitigate vulnerabilities before they can be exploited. This proactive approach is driven by the need to protect sensitive data, ensure compliance with regulations, and maintain customer trust in an environment where web applications are a critical part of the business landscape.

By Region, Asia Pacific will grow at the highest CAGR during the forecast period.

The adoption of security testing services in the Asia Pacific region is rapidly increasing due to the region’s expanding digital economy and the rising threat of cyberattacks. As busin

esses in Asia-Pacific embrace digital transformation and cloud computing, the need to identify and address vulnerabilities in their systems has become crucial. Regulatory pressures and growing awareness of cybersecurity risks are also driving organizations to invest in security testing solutions to ensure the resilience of their IT infrastructure and protect sensitive data from breaches. This trend is further fueled by the region’s diverse and complex threat landscape, prompting a proactive approach to cybersecurity.

Request Sample Pages@ https://www.marketsandmarkets.com/requestsampleNew.asp?id=150407261

Unique Features in the Security Testing Market

One unique feature driving the security testing market is the increasing sophistication and frequency of cyberattacks. As cybercriminals adopt advanced tactics, enterprises are compelled to implement security testing solutions that proactively identify and address vulnerabilities before they can be exploited.

Regulatory Compliance as a Growth Driver Another distinctive aspect of the security testing market is the strong influence of regulatory compliance requirements. Organizations must adhere to stringent standards such as GDPR, HIPAA, and PCI DSS to protect sensitive data and maintain customer trust.

Adoption of Automation and AI in Testing The growing adoption of automation, artificial intelligence (AI), and machine learning (ML) technologies is a unique trend in the security testing market. These technologies enable faster, more efficient, and accurate identification of vulnerabilities across complex IT environments.

Cloud-Based Security Testing Solutions Another unique feature is the shift toward cloud-based security testing solutions. As organizations increasingly migrate to cloud environments, the demand for security testing tools designed specifically for cloud infrastructures is on the rise.

Increased Focus on Application Security Lastly, the focus on application security is a notable feature in the market. With the rapid growth of web and mobile applications, ensuring the security of these applications has become a critical priority for businesses.

Major Highlights of the Security Testing Market

Rising Need for Proactive Vulnerability Detection Another key highlight is the growing need for proactive vulnerability detection. As cyberattacks become more frequent and complex, businesses are prioritizing the identification and mitigation of security flaws before they can be exploited.

Regulatory Compliance Driving Market Expansion A major driving force in the market is regulatory compliance. Stringent standards such as GDPR, HIPAA, and PCI DSS require organizations to implement regular security testing to ensure the protection of sensitive data and avoid penalties.

Increasing Adoption of AI and Automation The increasing integration of artificial intelligence (AI) and automation in security testing is another notable highlight. These technologies enhance the efficiency and accuracy of testing processes by enabling automated vulnerability detection, continuous monitoring, and predictive analysis.

Growth in Cloud-Based Security Solutions The market is also witnessing a significant shift toward cloud-based security testing solutions. With more organizations migrating to cloud infrastructures, the demand for security tools specifically designed for cloud environments has surged.

Inquire Before Buying@ https://www.marketsandmarkets.com/Enquiry_Before_BuyingNew.asp?id=150407261

Top Companies in the Security Testing Market

The security testing market is led by some of the globally established players, such as IBM (US), HCLTech (India), Synopsys (US), OpenText (UK), Cigniti (US), Qualitest (UK), Intertek (UK), DXC Technology (US), eInfochips (US), Checkmarx (US), HackerOne (US), Invicti (US), DataArt (US), Cobalt Labs (US), Trustwave (US), Contrast Security (US), Veracode (US), Qualys (US), OffSec (US), NCC Group (UK), GitHub (US), Bugcrowd (US), Applause (US), Rapid7 (US), and Parasoft (US). Partnerships, agreements, collaborations, acquisitions, and product developments are various growth strategies these players use to increase their market presence.

IBM (US) is a computer, technology, and IT consulting corporation. The company operates through various segments, such as cognitive solutions, global business services, technology services and cloud platforms, systems, and global financing. IBM’s clients comprise individual users, specialized businesses, and institutions, such as government, IT, defense, and educational organizations. In the category of security testing services, IBM offers X-Force Red Penetration Testing Services, X-Force Red Social Engineering Services, and X-Force Red Offensive Security Services. With the geographic presence across North America, Europe, Asia Pacific, the Middle East & Africa, and Latin America, the company caters to various industries, such as IT, healthcare, life sciences, government, telecom, automobile, manufacturing, chemicals and petroleum, electronics, energy and power, media and entertainment, mining, retail, BFSI, travel and transportation, education, and others.

Synopsys (Canada) provides advanced technologies for chip design, verification, IP integration, and software security and quality testing. The company’s security IP solutions segment includes a range of cryptography cores, security protocol accelerators and processors, embedded security IP modules, secure boot and cryptography middleware as well as content protection IP for integration into system-on-chips. These IP solutions also provide the highest levels of security for a range of products in the mobile, automotive, digital home, lot, and cloud computing markets. These integrated solutions enable the most efficient silicon design and the highest level of security to help prevent a wide range of evolving threats in connected devices. For security testing, Synopsys provides software tools such as Polaris, an AppSec which is used from development to deployment; Coverity which find security and quality defects in code; Seeker which automates web application security testing in DevOps; as well as Static Application Security Testing (SAST); Interactive Application Security Testing (IAST); and Defensics Fuzz Testing. It also provides services such as penetration testing services, MAST and others. With more than 30 years of experience, Synopsys has more than 14,000 employees and is present across North America, Europe, Asia Pacific, the Middle East & Africa, and Latin America.

Media Contact
Company Name: MarketsandMarkets™ Research Private Ltd.
Contact Person: Mr. Rohan Salgarkar
Email: Send Email
Phone: 18886006441
Address:1615 South Congress Ave. Suite 103
City: Delray Beach
State: FL 33445
Country: United States
Website: https://www.marketsandmarkets.com/Market-Reports/security-testing-market-150407261.html

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Security Testing Market Growing Trends, Business Growth, Size, Future Scope, Segmentation, Dynamics and Forecast to 2029

Stocks Driving Market Momentum with Groundbreaking Contracts and Technologies: LUNR, PRSO, LPTH, INBS, PNPN.V

Groundbreaking contracts and technological advancements across space exploration, environmental monitoring, high-grade mineral discovery, military and healthcare solutions, these five companies are setting the stage for significant market growth. Take a look now!

NASA has awarded Intuitive Machines (Nasdaq: LUNR) a Near Space Network contract valued at $4.82 billion to provide communication and navigation services from Earth’s surface to beyond the Moon. The 10-year contract, starting in October 2024, supports NASA’s Artemis campaign and includes the launch of Intuitive Machines’ lunar satellite constellation to enhance data transmission and autonomous operations. This contract solidifies Intuitive Machines’ leadership in space communications and bolsters its vision to commercialize lunar activities, creating new infrastructure for the lunar economy.

Peraso Inc. (NASDAQ: PRSO) has secured a key purchase order for its Perspectus module, leveraging advanced 60 GHz mmWave technology for military battlefield applications. The system enhances communication and situational awareness for soldiers through narrow-beamforming technology, reducing detection risk and interference. Equipped with power-saving features, the modules can operate continuously for up to a week on a single battery charge. With 40 granted patents and a strong innovation pipeline, Peraso is positioned as a leader in high-performance military and wireless communications technology. The stock closed flat on 7x its average 60-day volume, making it a stock to watch closely in the near term.

LightPath Technologies (NASDAQ: LPTH) has launched its next-gen Mantis™ camera, targeting the $500M furnace monitring market. Designed for power plants, the camera optimizes burn processes, enhances safety, and supports environmental compliance by reducing CO2 emissions, while supporting compliance with stringent environmental regulations in the U.S. and Europe. This marks LightPath’s shift toward advanced product solutions, with its first commercial order secured in the southeastern U.S.

Intelligent Bio Solutions Inc. (NASDAQ: INBS) shares surged this week, climbing 24% to $2.48 from Friday’s September 13, 2024 close of $2, following the release of promising financial data. The company reported preliminary unaudited sales figures of $0.73 million and $3.11 million for the fiscal year ending June 30, 2024. Additionally, INBS expects a 20% increase in cartridge sales and a 26% rise in reader sales compared to the previous year.

Power Nickel Inc. (TSX.V: PNPN) (OTCQB: PNPNF) has made a breakthrough at its Lion Zone discovery, with 10 out of 12 drill holes intercepting high-grade sulphide mineralization, significantly expanding the zone both laterally and vertically by 150 meters. With a fully funded 30,000-meter winter drill program set to capitalize on these results, Power Nickel is positioning itself for a world-class polymetallic discovery. As CEO Terry Lynch stated, this could be a company-defining moment, making now the ideal time for investors to get in on this rapidly growing opportunity. Power Nickel stock has experienced a surge in trading volume across both U.S. and Canadian markets, posting gains of approximately 23% on the TSX Venture and 24% on the OTCQB, significantly boosting shareholder value.

Intuitive Machines (Nasdaq: LUNR) lands a landmark contract, valued at up to $4.82 billion, Starting in October 2024. Meanwhile, companies like LightPath Technologies (NASDAQ: LPTH), Power Nickel (TSX.V: PNPN)(OTCQB: PNPNF), Peraso Inc. (NASDAQ: PRSO), and Intelligent Bio Solutions (NASDAQ: INBS) are making major strides in their respective fields, driving innovation and boosting investor interest.

Disclaimers: The Private Securities Litigation Reform Act of 1995 provides investors with a safe harbor with regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, assumptions, objectives, goals, and assumptions about future events or performance are not statements of historical fact and may be forward looking statements. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties that could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements, indicating certain actions & quotes; may, could or might occur Understand there is no guarantee past performance is indicative of future results. Investing in micro-cap or growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investor’s investment may be lost or due to the speculative nature of the companies profiled. TheStreetReports (TSR) is responsible for the production and distribution of this content.”TSR” is not operated by a licensed broker, a dealer, or a registered investment advisor. It should be expressly understood that under no circumstances does any information published herein represent a recommendation to buy or sell a security. “TSR” authors, contributors, or its agents, may be compensated for preparing research, video graphics, podcasts and editorial content. “TSR” has not been compensated to produce content related to “Any Companies” appearing herein. As part of that content, readers, subscribers, and everyone viewing this content are expected to read the full disclaimer in our website.

Media Contact
Company Name: The Street Reports
Contact Person: Editor
Email: Send Email
Country: United States
Website: http://www.thestreetreports.com

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: Stocks Driving Market Momentum with Groundbreaking Contracts and Technologies: LUNR, PRSO, LPTH, INBS, PNPN.V

B-Cell Lymphomas Pipeline Insights, Treatment Drugs, Clinical Trials, and Companies 2024

DelveInsight’s, “B-Cell Lymphoma Pipeline Insight 2024” report provides comprehensive insights about 160+ companies and 170+ pipeline drugs in B-Cell Lymphoma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Discover the latest drugs and treatment options in the B-Cell Lymphomas Pipeline. Dive into DelveInsight’s comprehensive report today! @ B-Cell Lymphomas Pipeline Outlook

Key Takeaways from the B-Cell Lymphomas Pipeline Report

In September 2024:- Pfizer- The purpose of this study is to learn about the effects of three study medicines [maplirpacept (PF-07901801), tafasitamab, and lenalidomide] when given together for the treatment of diffuse large B-cell lymphoma (DLBCL).
In September 2024:- Genmab- The purpose of the study is to examine efficacy and safety of epcoritamab with and without lenalidomide in newly diagnosed elderly patients with Diffuse Large B-Cell Lymphoma (DLBCL) who cannot tolerate anthracycline therapy. Epcoritamab (also known as EPKINLY™, GEN3013 and DuoBody®-CD3xCD20) is an antibody that has already been tested in several clinical studies. All patients will receive active treatment. There is an equal chance of receiving epcoritamab or epcoritamab plus lenalidomide.
DelveInsight’s B-Cell Lymphomas pipeline report depicts a robust space with 160+ active players working to develop 170+ pipeline therapies for B-Cell Lymphomas treatment.
The leading B-Cell Lymphomas Companies such as Oncternal Therapeutics, Inc., ZAI Lab, Pfizer, Xynomic Pharmaceuticals, SystImmune Inc., Autolus Limited, Vincerx Pharma, Ubix Therapeutics, Biomea Fusion Inc., Shanghai Hengrui Pharmaceutical, BeiGene, Hanmi Pharmaceutical, Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Merck Sharp & Dohme LLC, Sanofi, InnoCare Pharma, Allogene Therapeutics, Cellular Biomedicine Group Ltd., Genentech, Philogen, Aleta Biotherapeutics, Incyte Corporation, Fundamenta Therapeutics, Ltd., Juventas Cell Therapy, Shanghai Hengrui Pharmaceutical Co., Ltd., Guangzhou Lupeng Pharmaceutical Company LTD., TG Therapeutics Inc., Roche, 2seventy bio, AstraZeneca, Nektar Therapeutics, ADC Therapeutics, Genor Biopharma, Pacylex Pharmaceuticals, Antengene Corporation, Zhejiang DTRM Biopharma, Shanghai Cell Therapy Group Co., Ltd., Nanjing Legend Biotech Co, and others.
Promising B-Cell Lymphomas Therapies such as Selinexor, Rituximab, Cyclophosphamide, ME-401, and others.

Stay ahead with the most recent pipeline outlook for B-Cell Lymphomas. Get insights into clinical trials, emerging therapies, and leading companies with DelveInsight @ B-Cell Lymphomas Treatment Drugs

B-Cell Lymphoma Emerging Drugs

Odronextamab: ZAI Lab

Odronextamab is a human IgG4-based bispecific antibody that binds to CD3, a T-cell antigen associated with the T-cell receptor complex, and CD20, a B-cell surface antigen present on normal B cells and several B cell lineage malignancies. Odronextamab is currently being studied in a potentially pivotal Phase 2 study in B-cell non-Hodgkin lymphoma (B-NHL), including follicular lymphoma (FL), diffuse large B-cell lymphoma (DLBCL), and marginal zone lymphoma (MZL). In April 2020, Zai Lab obtained exclusive rights to develop and commercialize odronextamab in greater China from Regeneron Pharmaceuticals.

NKTR-255: Nektar Therapeutics

NKTR-255 is a biologic that targets the IL-15 pathway in order to activate the body’s innate and adaptive immunity. Through optimal engagement of the IL-15 receptor complex, NKTR-255 is designed to enhance functional NK cell populations and formation of long-term immunological memory, which may lead to sustained and durable anti-tumor immune response. Preclinical findings suggest NKTR-255 has the potential to synergistically combine with antibody-dependent cellular cytotoxicity molecules as well as to enhance CAR-T therapies. Currently the drug is in Phase II/III stage of Clinical trial evaluation for the treatment of Relapsed/Refractory Large B-cell Lymphoma.

Zilovertamab Vedotin: Merck Sharp & Dohme LLC

Zilovertamab vedotin is under development for the treatment of solid tumors, blood cancer including advanced or metastatic urothelial carcinoma of renal pelvis, ureter (upper urinary tract), bladder, or urethra, relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma, triple-negative breast cancer (TNBC), diffuse large B-cell lymphoma, or Richter transformation lymphoma. It is administered through intravenous route of administration. It acts by targeting ROR1 antigens expressing cells. The drug candidate is linked to UC-961-linker-monomethyl auristatin E (MMAE) ADC that preserves the high-affinity binding and specificity of UC-961 and allows for ROR1-targeted intracellular release of MMAE. Currently the drug is in Phase II/III stage of Clinical trial evaluation for the treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma.

Abexinostat: Xynomic Pharmaceuticals

Abexinostat (PCI-24781) is under development for the treatment of metastatic renal cell carcinoma, follicular lymphoma, non-Hodgkin lymphoma, diffuse large B-cell lymphoma, peripheral T-cell lymphoma, relapsed and refractory mantle cell lymphoma. It is formulated as a capsule and is administered through oral route. It acts by targeting histone deacetylase (HDAC). It was also under development for the treatment of lung cancer, colon cancer, gastric cancer, metastatic colorectal cancer, pancreatic cancer, nasopharyngeal cancer, haematological malignancies such as follicular non-Hodgkin lymphoma, and chronic lymphocytic leukemia (CLL) as second line of therapy, refractory and relapsed multiple myeloma as first and second line of therapy, refractory and relapsed acute myeloid leukemia, acute lymphoblastic leukemia, high or intermediary-2 risk myelodysplastic syndrome and sarcomas as second line of therapy, fallopian tube cancer, peritoneal cancer, brain tumor and neuroblastoma. Currently the drug is in Phase II stage of Clinical trial evaluation for the treatment of Diffuse Large B-cell Lymphoma.

Explore groundbreaking therapies and clinical trials in the B-Cell Lymphomas Pipeline. Access DelveInsight’s detailed report now! @ New B-Cell Lymphomas Drugs

B-Cell Lymphoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration

Oral
Parenteral
intravenous
Subcutaneous
Topical

B-Cell Lymphomas Products have been categorized under various Molecule types such as

Monoclonal Antibody
Peptides
Polymer
Small molecule
Gene therapy

Unveil the future of B-Cell Lymphomas Treatment. Learn about new drugs, pipeline developments, and key companies with DelveInsight’s expert analysis @ B-Cell Lymphomas Market Drivers and Barriers

Scope of the B-Cell Lymphomas Pipeline Report

Coverage- Global
B-Cell Lymphomas Companies- Oncternal Therapeutics, Inc., ZAI Lab, Pfizer, Xynomic Pharmaceuticals, SystImmune Inc., Autolus Limited, Vincerx Pharma, Ubix Therapeutics, Biomea Fusion Inc., Shanghai Hengrui Pharmaceutical, BeiGene, Hanmi Pharmaceutical, Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Merck Sharp & Dohme LLC, Sanofi, InnoCare Pharma, Allogene Therapeutics, Cellular Biomedicine Group Ltd., Genentech, Philogen, Aleta Biotherapeutics, Incyte Corporation, Fundamenta Therapeutics, Ltd., Juventas Cell Therapy, Shanghai Hengrui Pharmaceutical Co., Ltd., Guangzhou Lupeng Pharmaceutical Company LTD., TG Therapeutics Inc., Roche, 2seventy bio, AstraZeneca, Nektar Therapeutics, ADC Therapeutics, Genor Biopharma, Pacylex Pharmaceuticals, Antengene Corporation, Zhejiang DTRM Biopharma, Shanghai Cell Therapy Group Co., Ltd., Nanjing Legend Biotech Co, and others.
B-Cell Lymphomas Therapies- Selinexor, Rituximab, Cyclophosphamide, ME-401, and others.
B-Cell Lymphomas Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
B-Cell Lymphomas Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III

Get the latest on B-Cell Lymphomas Therapies and clinical trials. Download DelveInsight’s in-depth pipeline report today! @ B-Cell Lymphomas Companies, Key Products and Unmet Needs

Table of Content

Introduction
Executive Summary
B-Cell Lymphoma: Overview
Pipeline Therapeutics
Therapeutic Assessment
B-Cell Lymphoma – DelveInsight’s Analytical Perspective
Late Stage Products (Phase III)
Odronextamab: ZAI Lab
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Abexinostat: Xynomic Pharmaceuticals
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
TG 1801: TG Therapeutics Inc.
Drug profiles in the detailed report…..
Inactive Products
B-Cell Lymphoma Key Companies
B-Cell Lymphoma Key Products
B-Cell Lymphoma- Unmet Needs
B-Cell Lymphoma- Market Drivers and Barriers
B-Cell Lymphoma- Future Perspectives and Conclusion
B-Cell Lymphoma Analyst Views
B-Cell Lymphoma Key Companies
Appendix

About Us

Press Release Distributed by ABNewswire.com

To view the original version on ABNewswire visit: B-Cell Lymphomas Pipeline Insights, Treatment Drugs, Clinical Trials, and Companies 2024